Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1170 participants.
Also called NCT02058147
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,170 participants
- Sponsor
- Registry
-
NCT02058147 -
2013-003131-30
-
- Main results
- Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial
- Other papers using this trial's data
- Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial
- Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Chile, Czechia, Denmark, Estonia, France, Germany, Hungary, Italy, Latvia, Lithuania, Mexico, Poland, Romania, Russia, South Africa, Spain, Sweden, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02058147. Randomized; no masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2017-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
- Acronym
- LixiLan-O
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Insulin glargine/lixisenatide Fixed Ratio Combination
- Intervention (Drug)
- Insulin glargine (HOE901)
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02058147- Content hash
eeb8b695b21523e0a929d3211bddf872f2901cedd3bfdc8853475c773cc5fe16